Liquidia Corporation

NASDAQ•LQDA

CEO: Dr. Roger A. Jeffs Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2018-07-26

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

連絡先情報

419 Davis Drive, Suite 100, Morrisville, NC, 27560, United States

919-328-4400

www.liquidia.com

時価総額

$6.33B

PER (TTM)

281.0

24.5

配当利回り

52週高値

$72.71

52週安値

$11.85

52週レンジ

98%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

9年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2017-2025

財務ダッシュボード

Q1 2026 データ

売上高

$132.87M+0.00%

直近4四半期の推移

EPS

$0.60+0.00%

直近4四半期の推移

フリーCF

$50.16M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

YUTREPIA Drives Revenue Growth Net product sales reached $148.3M in 2025 following May FDA approval; total revenue grew 1,031% to $158.3M.

Net Loss Significantly Narrows Net loss decreased 46% to $68.9M in 2025, compared to $128.3M loss in 2024, reflecting initial commercial traction.

SG&A Expenses Surge Selling, general, and administrative expenses increased 93% to $157.2M, driven by YUTREPIA commercialization support and related litigation costs.

Treprostinil Service Revenue Drops Service revenue, tied to Treprostinil Injection profit share, fell 28% to $10.0M due to lower sales volumes in the current year.

リスク要因

Patent Litigation Threatens YUTREPIA Ongoing lawsuits seek injunctions potentially removing YUTREPIA from market or limiting label indications; outcome remains uncertain.

Sustained Profitability Uncertain History of losses and high expected expenses mean future viability depends on YUTREPIA revenue and securing additional external financing.

Reliance on Single Suppliers Dependence on sole suppliers for API, device (DPI), and packaging for YUTREPIA creates material disruption risk if supplies fail.

Treprostinil Pump Availability Risk Sales of Treprostinil Injection constrained as CADD-MS 3 pump support ends; replacement pump FDA clearance is uncertain.

見通し

Advance L606 Pivotal Study Planning worldwide placebo-controlled pivotal study for L606 treatment of PH-ILD; evaluating YUTREPIA for PH-COPD indication.

Scale Commercial Operations Focus commercial efforts on U.S. PAH/PH-ILD centers of excellence, leveraging targeted sales force and reimbursement specialists.

Build New Manufacturing Facility Leasing new 70,131 square foot facility in Morrisville, NC, for additional particle fabrication lines and supportive activities, expected to commence late 2026.

同業比較

売上高 (TTM)

GLPG

$1.21B

+262.2%

LQDA

$288.07M

+1936.7%

RCUS

$236.00M

+67.4%

粗利益率 (最新四半期)

IBRX

99.5%

-12.9pp

LQDA

90.9%

+29.3pp

RCUS

88.2%

-7.7pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
IBRX	$7.44B	-8.5	138.7%	173.9%
LQDA	$6.33B	281.0	46.8%	46.0%
COGT	$5.66B	-6.3	-83.3%	26.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

146.8%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

50%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年8月11日

EPS:$0.79

売上高:$170.98M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし